{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=4",
    "query": {
      "intervention": "Combination 400",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 1062,
    "total_pages": 107,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T07:41:06.714Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02411110",
      "title": "A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystitis, Interstitial",
        "Painful Bladder Syndrome"
      ],
      "interventions": [
        {
          "name": "LiRIS®",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "LiRIS Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 131,
      "start_date": "2015-05-21",
      "completion_date": "2017-01-09",
      "has_results": true,
      "last_update_posted_date": "2018-01-04",
      "last_synced_at": "2026-10-31T07:41:06.714Z",
      "location_count": 31,
      "location_summary": "Mobile, Alabama • Escondido, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02411110"
    },
    {
      "nct_id": "NCT01542788",
      "title": "Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "SOF",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match SOF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match RBV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 278,
      "start_date": "2012-03",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2014-05-19",
      "last_synced_at": "2026-10-31T07:41:06.714Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Coronado, California • Los Angeles, California + 40 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01542788"
    },
    {
      "nct_id": "NCT03621761",
      "title": "Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Telephone-based Cognitive Behavioral Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Modafinil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 343,
      "start_date": "2018-11-15",
      "completion_date": "2021-11-30",
      "has_results": true,
      "last_update_posted_date": "2022-12-27",
      "last_synced_at": "2026-10-31T07:41:06.714Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Seattle, Washington",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03621761"
    },
    {
      "nct_id": "NCT02278250",
      "title": "First in Human Study of M4344 in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "M4344 10 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 20 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 40 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 80 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 160 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 300 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 450 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 700 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 1050 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 1200 mg BIW",
          "type": "DRUG"
        },
        {
          "name": "M4344 100 mg BID",
          "type": "DRUG"
        },
        {
          "name": "M4344 150 mg QD",
          "type": "DRUG"
        },
        {
          "name": "M4344 250 mg QD",
          "type": "DRUG"
        },
        {
          "name": "M4344 350 mg QD",
          "type": "DRUG"
        },
        {
          "name": "M4344 400 mg",
          "type": "DRUG"
        },
        {
          "name": "M4344 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 97,
      "start_date": "2015-01-26",
      "completion_date": "2021-09-24",
      "has_results": true,
      "last_update_posted_date": "2023-03-16",
      "last_synced_at": "2026-10-31T07:41:06.714Z",
      "location_count": 8,
      "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02278250"
    },
    {
      "nct_id": "NCT05332002",
      "title": "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastro-Intestinal Cancer"
      ],
      "interventions": [
        {
          "name": "Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2022-07-13",
      "completion_date": "2027-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-31T07:41:06.714Z",
      "location_count": 6,
      "location_summary": "Hamilton, New Jersey • Lakewood, New Jersey • Long Branch, New Jersey + 2 more",
      "locations": [
        {
          "city": "Hamilton",
          "state": "New Jersey"
        },
        {
          "city": "Lakewood",
          "state": "New Jersey"
        },
        {
          "city": "Long Branch",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05332002"
    },
    {
      "nct_id": "NCT01183663",
      "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancers"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "5-fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2010-08",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-03",
      "last_synced_at": "2026-10-31T07:41:06.714Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01183663"
    },
    {
      "nct_id": "NCT04573504",
      "title": "Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Vaginal Laceration During Delivery"
      ],
      "interventions": [
        {
          "name": "Augmentin/Flagyl or Augmentin/Clindamycin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 274,
      "start_date": "2020-09-23",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-10-31T07:41:06.714Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04573504"
    },
    {
      "nct_id": "NCT00420355",
      "title": "Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "atazanavir",
          "type": "DRUG"
        },
        {
          "name": "lopinavir/ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 19,
      "start_date": "2007-04",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2009-02-06",
      "last_synced_at": "2026-10-31T07:41:06.714Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00420355"
    },
    {
      "nct_id": "NCT06982521",
      "title": "Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "PIK3CA Mutation",
        "HER2- Negative Breast Cancer",
        "Hormone Receptor Positive Tumor",
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Zovegalisib",
          "type": "DRUG"
        },
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Relay Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 540,
      "start_date": "2025-08-26",
      "completion_date": "2031-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-31T07:41:06.714Z",
      "location_count": 52,
      "location_summary": "Gilbert, Arizona • Beverly Hills, California • Duarte, California + 42 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06982521"
    },
    {
      "nct_id": "NCT01306058",
      "title": "Sorafenib and TRC105 in Hepatocellular Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatoma",
        "Liver Neoplasms",
        "Adenoma, Liver Cell",
        "Carcinoma, Hepatocellular",
        "Liver Neoplasms, Experimental"
      ],
      "interventions": [
        {
          "name": "TRC 105",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 27,
      "start_date": "2011-02-11",
      "completion_date": "2017-06-09",
      "has_results": true,
      "last_update_posted_date": "2019-01-23",
      "last_synced_at": "2026-10-31T07:41:06.714Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01306058"
    }
  ]
}